Structured evidence table for Soy Isoflavones Bone Markers Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Soy Isoflavones Bone Markers Randomized Trial | The high prevalence of osteoporosis and the increased fracture risk among the old and middle-aged can be seen due to rapid and continuous bone resorption, as opposed to growth time when bone formation surpasses bone resorption. | 3 | Hooshiar Saeedeh Hosseini (2022) | Soy Isoflavones and Bone Health: Focus on the RANKL/RANK/OPG Pathway |
| Soy Isoflavones Bone Markers Randomized Trial | Osteoporosis is specified by the deterioration of bone tissue microarchitecture and reduction of bone mass, which causes an enhanced risk of fracture and fragility of bone []. | 3 | Hooshiar Saeedeh Hosseini (2022) | Soy Isoflavones and Bone Health: Focus on the RANKL/RANK/OPG Pathway |
| Soy Isoflavones Bone Markers Randomized Trial | Skeletal and extra-skeletal risk factors and age are related to osteoporotic fractures incidence [–]. | 3 | Hooshiar Saeedeh Hosseini (2022) | Soy Isoflavones and Bone Health: Focus on the RANKL/RANK/OPG Pathway |
| Soy Isoflavones Bone Markers Randomized Trial | 1 2 3 4 6 4 5 7 8 9 10 12 13 14 12 15 Bone, as active tissue, continuously remodels throughout life []. | 3 | Hooshiar Saeedeh Hosseini (2022) | Soy Isoflavones and Bone Health: Focus on the RANKL/RANK/OPG Pathway |
| Soy Isoflavones Bone Markers Randomized Trial | Results The combined EUE and Isf treatment significantly improved biomechanical performance of the femur and restored bone mineral content in ovariectomized rats. | 4 | Zhao R (2026) | Eucommia ulmoides extract and soy isoflavones attenuate postmenopausal osteoporosis by modulating bone-specific transcription factors and inflammatory signaling pathways. |
| Soy Isoflavones Bone Markers Randomized Trial | Levels of bone formation markers were elevated, whereas indices of bone resorption were reduced. | 4 | Zhao R (2026) | Eucommia ulmoides extract and soy isoflavones attenuate postmenopausal osteoporosis by modulating bone-specific transcription factors and inflammatory signaling pathways. |
| Soy Isoflavones Bone Markers Randomized Trial | In vitro , the combination enhanced osteoblast mineralization and proliferation, suppressed osteoclast formation, and increased osteoclast apoptosis. | 4 | Zhao R (2026) | Eucommia ulmoides extract and soy isoflavones attenuate postmenopausal osteoporosis by modulating bone-specific transcription factors and inflammatory signaling pathways. |
| Soy Isoflavones Bone Markers Randomized Trial | Background Postmenopausal osteoporosis (PMO) is driven by estrogen deficiency, enhanced osteoclastic activity, impaired osteoblast function, and persistent inflammatory signaling. | 4 | Zhao R (2026) | Eucommia ulmoides extract and soy isoflavones attenuate postmenopausal osteoporosis by modulating bone-specific transcription factors and inflammatory signaling pathways. |
Source documents